# Monoclonal B-cell lymphocytosis
**Monoclonal B-cell lymphocytosis** (MBL) is an asymptomatic condition defined by the presence of a clonal B-cell population in the peripheral blood at a count below 5 × 10⁹/L, without lymphadenopathy, organomegaly, cytopenias, or other features of a B-cell lymphoproliferative disorder.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC4624440/) • [2](https://www.sciencedirect.com/science/article/pii/S1521692619300374) The majority of cases carry the immunophenotype (pattern of surface proteins identifying a cell type) of chronic lymphocytic leukemia (CLL), and MBL is considered a precursor state to CLL, although most cases never progress.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC4624440/) • [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631769/)
| Key fact | Detail |
|---|---|
| Definition | Clonal B-cell population in peripheral blood, count below 5 × 10⁹/L, persisting at least 3 months, with no lymphadenopathy, organomegaly, cytopenias, or other features of a lymphoproliferative disorder[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397339/) |
| Subtypes | Low-count (below 0.5 × 10⁹/L clonal B cells) and high-count (0.5 to below 5 × 10⁹/L); the fifth edition WHO classification recognizes low-count, CLL/SLL-type, and non-CLL/SLL-type MBL[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397339/) • [5](https://pmc.ncbi.nlm.nih.gov/articles/PMC9214472/) |
| Prevalence | Low-count MBL is detectable in about 5% of adults over age 40 using standard-sensitivity flow cytometry; overall prevalence is at least 100 times that of CLL[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC4624440/) • [6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/) |
| Progression | High-count MBL progresses to CLL requiring therapy at 1% to 2% per year; low-count MBL rarely progresses and needs no specific follow-up[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC4624440/) • [7](https://pubmed.ncbi.nlm.nih.gov/24896545/) |
| Origin of term | Coined in 2005 by the International Familial CLL Consortium in *British Journal of Haematology*[8](https://pubmed.ncbi.nlm.nih.gov/16042682/) |
| Risk stratification | In a Mayo Clinic cohort, the CLL-IPI assigned MBL patients a 5-year risk of needing therapy of 7% (low), 14% (intermediate), and 40% (high/very high)[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC8288657/) |
## Definition and diagnosis
The diagnostic criteria require detection of a monoclonal B-cell population by flow cytometry, most commonly through light-chain restriction, meaning an overall kappa:lambda ratio above 3:1 or below 0.3:1, or more than 25% of B cells lacking or showing low surface immunoglobulin expression.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/) The clonal population must show a disease-specific immunophenotype, the absolute B-cell count must remain below 5 × 10⁹/L, and the physical examination must be normal, with no lymphadenopathy or organomegaly and no B-symptoms such as fever, weight loss, or night sweats attributable to lymphoma.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/) When possible, a repeat assessment should demonstrate that the finding is stable over a three-month period.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/)
The count threshold separates MBL from CLL, which is defined by more than 5 × 10⁹/L B cells in the peripheral blood. [Small lymphocytic lymphoma](https://www.edgepedia.org/small-lymphocytic-lymphoma) shares the low blood count but shows lymph node, liver, or spleen enlargement.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/)
**Immunophenotypic categories.** Most MBL cases have a CLL-like phenotype: coexpression of CD5 with CD19, low CD20, and CD23, with low surface immunoglobulin, a profile phenotypically identical to CLL B cells.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/) Atypical CLL phenotype cases coexpress CD5 and CD19 but show strong CD20 or lack CD23, and t(11;14) must be excluded to rule out mantle cell lymphoma. Non-CLL phenotype cases are CD5 negative with CD20 expression and moderate to strong surface immunoglobulin.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/)
## History
The first published description of these abnormal B cells dates to 1991, in a report from a Centers for Disease Control health study that detected monoclonal B cells in people living near hazardous waste sites in the United States.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/) A 1995 public health service workshop proposed case definitions and follow-up recommendations, and studies through the following decade recognized CD5-positive and CD5-negative monoclonal B lymphocytes in people with no clinically apparent hematological disease.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/)
In 2005 the International Familial CLL Consortium, in a paper by Gerald E. Marti and colleagues, proposed the term monoclonal B-cell lymphocytosis and a working definition for clinical, epidemiological, and laboratory studies.[8](https://pubmed.ncbi.nlm.nih.gov/16042682/) MBL was established as an entity in the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, and absolute neoplastic B-cell counts gained formal importance in distinguishing MBL from CLL in the 2017 WHO classification.[10](https://www.cytometry.org/web/modules/Module_23.pdf)
## Classification
MBL is divided by clonal B-cell count into low-count and high-count forms at the threshold of 0.5 × 10⁹/L.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397339/) The two forms differ in how they are found: low-count MBL is typically identified in population screening studies using highly sensitive flow cytometry, with a median clonal count of 0.001 × 10⁹/L, while high-count MBL, sometimes called clinical MBL, is typically identified during evaluation of low-level lymphocytosis, with a median count of 2.9 × 10⁹/L.[7](https://pubmed.ncbi.nlm.nih.gov/24896545/)
The fifth edition of the WHO Classification of Haematolymphoid Tumours (WHO-HAEM5) recognizes three subtypes: low-count MBL, meaning a clonal CLL/SLL-phenotype B-cell count below 0.5 × 10⁹/L; CLL/SLL-type MBL, with a monoclonal CLL/SLL-phenotype count of at least 0.5 × 10⁹/L and a total B-cell count below 5 × 10⁹/L; and non-CLL/SLL-type MBL at any count below 5 × 10⁹/L.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC9214472/) • [11](https://doi.org/10.1136/jcp-2025-210260) MBL and CLL/SLL together form the WHO-HAEM5 family of pre-neoplastic and neoplastic small lymphocytic proliferations.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC9214472/)
## Epidemiology
Low-count MBL can be detected in about 5% of adults over the age of 40 when assessed with standard-sensitivity flow cytometry.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC4624440/) [Prevalence](https://www.edgepedia.org/prevalence) rises with age: in one study of United Kingdom hospital outpatients with normal blood counts, overall prevalence of CLL-like MBL was 3.5%, increasing from 2.1% at ages 40 to 60 to 5.0% over age 60.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/) Published prevalence figures across studies range from 0.14% to 12.0%, a variation attributed to different flow cytometry approaches.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/)
**Familial clustering.** MBL is more frequent in relatives of CLL patients. In the Genetic Epidemiology of CLL consortium cohort, 22% of 1,045 relatives from 310 families with two or more members with CLL were found to have MBL.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397339/) A polygenic risk score integrating 41 CLL susceptibility single nucleotide polymorphisms was associated with an approximately 2.5-fold increased risk of CLL and with odds ratios of 1.75 for low-count and 2.14 for high-count MBL.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397339/)
## Natural history and risk stratification
The absolute clonal B-cell count is the strongest predictor of progression.[12](https://journals.sagepub.com/doi/pdf/10.1177/107327481201900102) Low-count MBL has an exceedingly small risk of progression to CLL, and these patients do not require specific follow-up.[7](https://pubmed.ncbi.nlm.nih.gov/24896545/) High-count MBL progresses to CLL requiring therapy at a rate of 1% to 2% per year.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC4624440/) In the GEC cohort, considering only individuals with low-count MBL, the 5-year cumulative incidence was 5.7%, with progression to CLL, defined as exceeding 5 × 10⁹/L monoclonal B cells, at about 1.1% per year.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397339/)
In a prospective United Kingdom cohort, Rawstron and colleagues monitored 185 subjects with CLL-phenotype MBL and lymphocytosis for a median of 6.7 years; 28 subjects (15% of the cohort) progressed to a diagnosis of CLL, and 13 (7%) required chemotherapy, while the absolute B-cell count was the only independent prognostic factor for progressive lymphocytosis.[13](https://pmc.ncbi.nlm.nih.gov/articles/PMC3913172/)
**Biology of the two subtypes.** High-count MBL shares biological and clinical features with indolent CLL, whereas low-count MBL appears distinct and may represent an immunological rather than a pre-malignant condition.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631769/) Both subtypes can carry CLL-specific genomic aberrations such as cytogenetic abnormalities and gene mutations, but to a much lesser extent than CLL, suggesting these aberrations are mostly relevant to progression rather than onset.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631769/) Unmutated IGHV somatic hypermutation status and CLL-related cytogenetic aberrations are risk factors for progression from MBL to CLL and for shorter overall survival.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631769/)
**Prognostic indexing.** The chronic lymphocytic leukemia-international prognostic index (CLL-IPI) predicts outcomes in MBL. In a [Mayo Clinic](https://www.edgepedia.org/mayo-clinic) cohort of 415 MBL and 554 Rai stage 0 CLL patients followed for a median of 7 years, the risk of progression needing therapy was 2.9% per year for MBL and 5% per year for Rai 0 CLL, and the estimated 5-year risk of first treatment by CLL-IPI risk group was 13.5% (low), 30% (intermediate), and 58% (high/very high) across the combined cohort.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC8288657/)
## Clinical management
Management depends on the subtype. Individuals with low-count, population-screening MBL need no specific monitoring beyond routine medical care and an annual complete blood count.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/) Patients with clinical CLL-like MBL are followed annually by a hematologist with a complete blood count and counseled to watch for symptoms such as lymph node enlargement, night sweats, extreme fatigue, and weight loss.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/) Many investigators recommend clinical and laboratory evaluation every 6 to 12 months for clinical MBL, scaled to the circulating clonal B-cell count.[14](https://pmc.ncbi.nlm.nih.gov/articles/PMC4000465/)
Patients with atypical or non-CLL-like MBL require more thorough evaluation, including FISH testing for t(11;14), CT imaging, and bone marrow biopsy, because some of these cases represent non-[Hodgkin lymphoma](https://www.edgepedia.org/hodgkin-lymphoma) subtypes; those with an immunophenotype and cytogenetics suggestive of mantle cell lymphoma are followed every 3 to 6 months with CT imaging at least every 6 months.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/)
**Supportive considerations.** Like patients with Rai stage 0 CLL, individuals with high-count MBL have increased risks of infections and second cancers, although the risk of progression requiring treatment and the potential to shorten life expectancy are greater for CLL.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC4624440/) Overall survival of high-count MBL patients collectively is similar to the age- and sex-matched general population, though 5-year survival appears slightly lower for those with higher-risk biologic parameters.[7](https://pubmed.ncbi.nlm.nih.gov/24896545/) Consensus guidance holds that screening for MBL outside clinical trials is not recommended, and that adherence to age-appropriate cancer screening should be maintained.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397339/)
## References
1. [Parikh SA, Kay NE, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. PMC4624440.](https://pmc.ncbi.nlm.nih.gov/articles/PMC4624440/)
2. [Monoclonal B-cell lymphocytosis. ScienceDirect, Best Practice & Research Clinical Haematology.](https://www.sciencedirect.com/science/article/pii/S1521692619300374)
3. [Understanding Monoclonal B Cell Lymphocytosis: An Interplay of Genetic and Microenvironmental Factors. PMC8631769.](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631769/)
4. [State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee. PMC12397339.](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397339/)
5. [The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. PMC9214472.](https://pmc.ncbi.nlm.nih.gov/articles/PMC9214472/)
6. [Matos DM, Falcão RP. Monoclonal B-cell lymphocytosis: a brief review for general clinicians. Sao Paulo Med J. PMC10866320.](https://pmc.ncbi.nlm.nih.gov/articles/PMC10866320/)
7. [Parikh SA, Kay NE, Shanafelt TD. Monoclonal B-cell lymphocytosis: update on diagnosis, clinical outcome, and counseling. Clin Adv Hematol Oncol. PMID 24896545.](https://pubmed.ncbi.nlm.nih.gov/24896545/)
8. [Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130(3):325-32. PMID 16042682.](https://pubmed.ncbi.nlm.nih.gov/16042682/)
9. [The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. PMC8288657.](https://pmc.ncbi.nlm.nih.gov/articles/PMC8288657/)
10. [Absolute neoplastic B-cell counts in the WHO Classification (Module 23), cytometry.org.](https://www.cytometry.org/web/modules/Module_23.pdf)
11. [Fifth edition WHO classification: mature B-cell neoplasms. Journal of Clinical Pathology.](https://doi.org/10.1136/jcp-2025-210260)
12. [Clinical Aspects of Monoclonal B-Cell Lymphocytosis. Cancer Control, SAGE.](https://journals.sagepub.com/doi/pdf/10.1177/107327481201900102)
13. [Monoclonal B-cell Lymphocytosis (MBL): Biology, Natural History, and Clinical Management. PMC3913172.](https://pmc.ncbi.nlm.nih.gov/articles/PMC3913172/)
14. [Monoclonal B-Cell Lymphocytosis. PMC4000465.](https://pmc.ncbi.nlm.nih.gov/articles/PMC4000465/)
---
*Topic: Encyclopedia › Life and health › Human health and medicine › Diseases and injuries › Cardiovascular and blood conditions › Blood disorders (hematologic conditions) › Leukemias › Chronic lymphocytic leukemia › CLL diagnosis, criteria, and staging*
*Initially written Sep 17, 2026 · Reviewed: Sep 17, 2026; Sep 30, 2026; Oct 21, 2026 · Edited: Sep 30, 2026; Oct 21, 2026 · Last review: Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license